Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-08-29FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for Taclonex (calcipotriol and betamethasone dipropionate) from LEO Pharma Inc. The notice indic…
-
CLINICAL_TRIALS trial_result · 2014-08-29Clinical Trial Update: RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
The RESTORE study evaluating safety and treatment optimization for efalizumab (Raptiva) in plaque psoriasis has been terminated.
-
CLINICAL_TRIALS trial_result · 2014-08-27Clinical Trial Update: Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis [Phase 3]
Phase 3 trial update evaluating safety and effectiveness of Clobex Spray followed by Calcitriol Ointment for plaque psoriasis; trial complet…
-
CLINICAL_TRIALS trial_result · 2014-08-26Clinical Trial Update: A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating two dosing regimens of alefacept in adults with moderate to severe chronic plaque psoriasis has completed. The spon…
-
CLINICAL_TRIALS trial_result · 2014-08-26Clinical Trial Update: A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate [Phase 3]
Phase 3 trial evaluating the efficacy and safety of Alefacept in chronic plaque psoriasis patients who failed or were unsuitable for convent…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-08-07Clinical Trial Update: Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating desoximetasone spray 0.25% for moderate-to-severe plaque psoriasis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2014-08-07Clinical Trial Update: Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
A completed clinical trial update assessing the real-world effectiveness of adalimumab (Humira) for scalp and nail involvement in patients w…
-
FDA approval · 2014-07-28FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for TACLONEX (calcipotriene and betamethasone dipropionate) from LEO Pharma Inc. The approval update…
-
FDA approval · 2014-07-28FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)
FDA approves Prasco Laboratories' supplemental application for calcipotriene and betamethasone dipropionate, a generic topical treatment for…
-
FDA approval · 2014-07-28FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for OTEZLA (apremilast) from Amgen, potentially expanding or updating its label.
-
CLINICAL_TRIALS withdrawal · 2014-07-15Clinical Trial Update: Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy [Phase 2]
Phase 2 clinical trial of apremilast for chronic plaque psoriasis in patients who failed biologic therapy was withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-07-11Clinical Trial Update: SHP-141C in Plaque Type Psoriasis [Phase 1]
Phase 1 clinical trial of SHP-141C for plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2014-07-11Clinical Trial Update: Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% [Phase 4]
Phase 4 trial update evaluating subject-reported target-lesion numeric rating scale in plaque psoriasis treated with Clobex spray 0.05%.
-
CLINICAL_TRIALS trial_result · 2014-07-03Clinical Trial Update: Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating Desoximetasone spray 0.25% for moderate to severe plaque psoriasis; results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-06-30Clinical Trial Update: An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
An observational study assessing real-world management of plaque psoriasis patients treated with etanercept (Enbrel) under new reimbursement…
-
FDA approval · 2014-06-19FDA Approved: DESOXIMETASONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Desoximetasone from Sun Pharmaceutical Industries, indicating approval of a supplemental for…
-
FDA approval · 2014-06-12FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for calcipotriene and betamethasone dipropionate topical by Prasco Laboratories, authorizing a suppl…
-
CLINICAL_TRIALS trial_result · 2014-06-11Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022) [Phase 1]
This Phase 1 study evaluated the safety, pharmacokinetics, and preliminary efficacy of MK-0873 for plaque psoriasis and has completed with r…
-
FDA approval · 2014-05-30FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited under BLA125057.
-
CLINICAL_TRIALS trial_result · 2014-05-20Clinical Trial Update: An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis [Phase 3]
This Phase 3 trial update reports efficacy and safety results of ustekinumab in adults with plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2014-05-12Clinical Trial Update: Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis [Phase 3]
Phase 3 data compare fumaric acid alone versus fumaric acid plus narrow-band UVB phototherapy for plaque psoriasis. The study status is comp…
-
CLINICAL_TRIALS trial_result · 2014-05-05Clinical Trial Update: A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis [Phase 2]
Phase 2 trial evaluating the safety and effectiveness of doxercalciferol capsules in participants with moderate to severe chronic plaque pso…
-
CLINICAL_TRIALS trial_result · 2014-05-02Clinical Trial Update: Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating etanercept 50 mg once weekly with an as-needed topical agent for moderate-to-severe plaque psoriasis; results and s…
-
FDA approval · 2014-03-21FDA Approved: OTEZLA — Original Application (Amgen, Inc)
FDA approved OTEZLA (apremilast) from Amgen in its Original Application for the treatment of plaque psoriasis and psoriatic arthritis.
-
CLINICAL_TRIALS trial_result · 2014-03-20Clinical Trial Update: A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g [Phase 3]
This update reports the completion of a Phase 3 safety study of Raptiva (efalizumab) in adults with plaque psoriasis previously enrolled in …